Platinum-resistant Ovarian Cancer Enrolling by Invitation Phase 1 Trials for Mirvetuximab soravtansine (DB12489)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Enrolling by Invitation1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05483933Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersTreatment